## WHAT IS CLAIMED IS:

1. A method for alkylating a glycopeptide that comprises a saccharide-amine comprising:

combining an aldehyde or ketone, a suitable base, and the glycopeptide or a salt thereof, to provide a reaction mixture;

acidifying the reaction mixture; and

combining the reaction mixture with a suitable reducing agent, to provide a glycopeptide that is alkylated at the saccharide-amine.

- The method of claim 1 wherein the glycopeptide comprises at least one aminogroup other than the saccharide-amine.
  - 3. The method of claim 2 wherein reductive alkylation at the saccharide-amine is favored over reductive alkylation at the other amino group of the glycopeptide by at least about 10:1.
- 4. The method of claim 2 wherein reductive alkylation at the saccharide-amine is favored over reductive alkylation at the other amino group of the glycopeptide by at least about 20:1.
  - 5. The method of claim 1 wherein the reductive alkylation is carried out in the presence of a suitable solvent.
- 6. The method of claim 5 wherein the solvent is a halogenated hydrocarbon, a linear or branched ether, an aromatic hydrocarbon, an alcohol, dimethylsulfoxide, N,N-dimethylformamide, acetonitrile, water, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-

pyrimidone, tetramethyl urea, N,N-dimethylacetamide, diethylformamide, 1-methyl-2-pyrrolidinone, tetramethylenesulfoxide, glycerol, ethyl acetate, isopropyl acetate, N,N-dimethylpropylene urea, or dioxane, or a mixture thereof.

- 7. The method of claim 6 wherein the solvent is acetonitrile, water, DMF, or methanol, or mixtures thereof.
  - 8. The method of claim 1 wherein the reaction mixture that is combined with the reducing agent comprises a protic solvent.
  - 9. The method of claim 1 wherein the reductive alkylation is carried out at a temperature in a range of about 0 °C to about 50 °C.
- 10 10. The method of claim 1 wherein the base is a tertiary amine.
  - 11. The method of claim 1 wherein the acid is a carboxylic acid or a mineral acid.
  - 12. The method of claim 1 wherein the acid is trifluoroacetic acid.
  - 13. The method of claim 1 wherein the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, pyridine/borane, sodium borohydride, or zinc borohydride.
  - 14. The method of claim 1 wherein the reducing agent is a hydrogen source and a transition metal catalyst.
  - 15. The method of claim 1 further comprising isolating the alkylated glycopeptide.

16. A method for preparing an alkylated glycopeptide comprising: combining an aldehyde or ketone, a suitable base, and a compound of formula I:

wherein:

5

10

R<sup>1</sup> is an amino saccharide group;

R<sup>2</sup> is hydrogen or a saccharide group;

 $R^{3} \text{ is } R^{3} \text{ is } -OR^{c}, -NR^{c}R^{c}, -O-R^{a}-Y-R^{b}-(Z)_{x}, -NR^{c}-R^{a}-Y-R^{b}-(Z)_{x}, -NR^{c}R^{e}, \text{ or } -O-R^{e};$ 

 $R^4$  is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, substituted alkynyl,- $C(O)R^d$  and a saccharide group;

 $R^5 \ is \ selected \ from \ the \ group \ consisting \ of \ hydrogen, \ halo, \ -CH(R^c)-NR^cR^c, \\ -CH(R^c)-NR^cR^e, \ -CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x, -CH(R^c)-R^x, \ and \\ -CH(R^c)-NR^c-R^a-C(=O)-R^x;$ 

R<sup>6</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, -C(O)R<sup>d</sup> and a saccharide group;

R<sup>7</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, substituted alkynyl, and -C(O)R<sup>d</sup>;

R<sup>8</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R<sup>9</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

 $R^{10}$  is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; or  $R^8$  and  $R^{10}$  are joined to form  $-Ar^1-O-Ar^2-$ , where  $Ar^1$  and  $Ar^2$  are independently arylene or heteroarylene;

R<sup>11</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R<sup>10</sup> and R<sup>11</sup> are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

R<sup>12</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic,

15

20

10

5

25

10

15

25

-C(O)R<sup>d</sup>, -C(NH)R<sup>d</sup>, -C(O)NR<sup>c</sup>R<sup>c</sup>, -C(O)OR<sup>d</sup>, and -C(NH)NR<sup>c</sup>R<sup>c</sup>, or R<sup>11</sup> and R<sup>12</sup> are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

R<sup>13</sup> is selected from the group consisting of hydrogen or -OR<sup>14</sup>;

R<sup>14</sup> is selected from hydrogen, -C(O)R<sup>d</sup> and a saccharide group;

each R<sup>a</sup> is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R<sup>b</sup> is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkynylene and substituted alkynylene;

each  $R^c$  is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and  $-C(O)R^d$ ;

each R<sup>d</sup> is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R<sup>e</sup> is a saccharide group;

20 R<sup>x</sup> is a nitrogen-linked amino saccharide or a nitrogen-linked heterocycle; X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> are independently selected from hydrogen or chloro; each Y is independently selected from the group consisting of oxygen, sulfur,

$$-S-S-, -NR^{c}-, -S(O)-, -SO_{2}-, -NR^{c}C(O)-, -OSO_{2}-, -OC(O)-, -NR^{c}SO_{2}-,$$

$$-C(O)NR^{\circ}-, -C(O)O-, -SO_{2}NR^{\circ}-, -SO_{2}O-, -P(O)(OR^{\circ})O-, -P(O)(OR^{\circ})NR^{\circ}-, -(O)(OR^{\circ})NR^{\circ}-, -($$

$$-\mathrm{OP}(\mathrm{O})(\mathrm{OR}^{\mathrm{c}})\mathrm{O}-,-\mathrm{OP}(\mathrm{O})(\mathrm{OR}^{\mathrm{c}})\mathrm{NR}^{\mathrm{c}}-,-\mathrm{OC}(\mathrm{O})\mathrm{O}-,-\mathrm{NR}^{\mathrm{c}}\mathrm{C}(\mathrm{O})\mathrm{O}-,-\mathrm{NR}^{\mathrm{c}}\mathrm{C}(\mathrm{O})\mathrm{NR}^{\mathrm{c}}-,$$

 $-OC(O)NR^{c}$ -, -C(=O)-, and  $-NR^{c}SO_{2}NR^{c}$ -;

each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, 1 or 2; and

x is 1 or 2;

or a stereoisomer or salt thereof; to provide a reaction mixture;

acidifying the reaction mixture; and

combining the reaction mixture with a suitable reducing agent, to provide the corresponding glycopeptide alkylated at the amino group of the amino saccharide.

17. The method of claim 16 wherein R<sup>1</sup> is an amino saccharide of formula (III):

- wherein  $R^{15}$  is H; and  $R^{16}$  is hydrogen or methyl.
  - 18. The method of claim 16 wherein R<sup>2</sup>, R<sup>4</sup>, R<sup>6</sup>, and R<sup>7</sup> are each hydrogen.
  - 19. The method of claim 16 wherein  $R^3$  is -OH.
  - 20. The method of claim 16 wherein  $R^5$  is hydrogen,  $-CH_2$ -NHR°,  $-CH_2$ -NR°R° or  $-CH_2$ -NH-R°- $-(Z)_x$ .

- 21. The method of claim 16 wherein the alkylated glycopeptide is a compound of formula I wherein  $R^1$  is an amino saccharide wherein the saccharide-amine is substituted with- $R^a$ -Y- $R^b$ - $(Z)_x$ , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, or substituted cycloalkenyl.
- 22. The method of claim 16 wherein the alkylated glycopeptide is a compound of formula I wherein R<sup>1</sup> is an amino saccharide wherein the saccharide-amine is substituted with -CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-(CH<sub>2</sub>')<sub>9</sub>CH<sub>3</sub>;
- $\begin{array}{ll} -\mathrm{CH_2CH_2-NHSO_2-(CH_2)_{11}CH_3;} -\mathrm{CH_2CH_2-S-(CH_2)_8CH_3;} -\mathrm{CH_2CH_2-S-(CH_2)_9CH_3;} \\ -\mathrm{CH_2CH_2-S-(CH_2)_{10}CH_3;} -\mathrm{CH_2CH_2CH_2-S-(CH_2)_8CH_3;} -\mathrm{CH_2CH_2CH_2-S-(CH_2)_9CH_3;} \\ -\mathrm{CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3} (\mathit{trans}); -\mathrm{CH_2CH_2CH_2-S-(CH_2)_7CH_3;} \\ -\mathrm{CH_2CH_2-S(O)-(CH_2)_9CH_3;} -\mathrm{CH_2CH_2-S-(CH_2)_6Ph;} -\mathrm{CH_2CH_2-S-(CH_2)_8Ph;} \\ -\mathrm{CH_2CH_2-S-(CH_2)_8Ph;} -\mathrm{CH_2CH_2-NH-CH_2-4-(4-Cl-Ph)-Ph;} \end{array}$
- $\begin{array}{lll} -\mathrm{CH_2CH_2-NH-CH_2-4-[4-(CH_3)_2CHCH_2-]-Ph;} & -\mathrm{CH_2CH_2-NH-CH_2-4-(4-CF_3-Ph)-Ph;} \\ -\mathrm{CH_2CH_2-S-CH_2-4-(4-Cl-Ph)-Ph;} & -\mathrm{CH_2CH_2-S(O)-CH_2-4-(4-Cl-Ph)-Ph;} \\ -\mathrm{CH_2CH_2CH_2-S-CH_2-4-(4-Cl-Ph)-Ph;} & -\mathrm{CH_2CH_2CH_2-S(O)-CH_2-4-(4-Cl-Ph)-Ph;} \\ -\mathrm{CH_2CH_2CH_2-S-CH_2-4-[3,4-di-Cl-PhCH_2O-)-Ph;} & -\mathrm{CH_2CH_2-NHSO_2-CH_2-4-[4-(4-Cl-Ph)-Ph;} \\ -\mathrm{CH_2CH_2CH_2-S-CH_2-4-[3,4-di-Cl-PhCH_2O-)-Ph;} & -\mathrm{CH_2CH_2-NHSO_2-CH_2-4-[4-(4-Cl-Ph)-Ph;} \\ \end{array}$
- $-CH_2CH_2CH_2-NHSO_2-CH_2-4-(Ph-C\equiv C-)-Ph; -CH_2CH_2CH_2-NHSO_2-4-(4-Cl-Ph)-Ph;$  or  $-CH_2CH_2CH_2-NHSO_2-4-(naphth-2-yl)-Ph.$ 
  - 23. The method of claim 17 wherein the alkylated glycopeptide is a compound of formula I wherein  $R^1$  is a saccharide group of formula III, wherein  $R^{15}$  is  $-R^a-Y-R^b-(Z)_x$ , alkyl, substituted alkyl, alkenyl, substituted alkynyl,

substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl.

- 24. The method of claim 23 wherein R<sup>15</sup> is -CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
- -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>;
- 5  $-CH_2CH_2-NHSO_2-(CH_2)_9CH_3$ ;  $-CH_2CH_2-NHSO_2-(CH_2)_{11}CH_3$ ;
  - $-CH_2CH_2-S-(CH_2)_8CH_3$ ;  $-CH_2CH_2-S-(CH_2)_9CH_3$ ;  $-CH_2CH_2-S-(CH_2)_{10}CH_3$ ;
  - -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>3</sub>-CH=CH-(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub> (trans); -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>;
  - -CH<sub>2</sub>CH<sub>2</sub>-S(O)-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>6</sub>Ph; -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>8</sub>Ph;
- 10  $-CH_2CH_2CH_2-S-(CH_2)_8Ph; -CH_2CH_2-NH-CH_2-4-(4-Cl-Ph)-Ph;$ 
  - -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-[4-(CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-]-Ph; -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-CF<sub>3</sub>-Ph)-Ph;
  - -CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph; -CH<sub>2</sub>CH<sub>2</sub>-S(O)-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
  - -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S(O)-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
  - -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-[3,4-di-Cl-PhCH<sub>2</sub>O-)-Ph; -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-CH<sub>2</sub>-4-[4-(4-
- 15 Ph)-Ph]-Ph; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
  - $-CH_2CH_2CH_2-NHSO_2-CH_2-4-(Ph-C=C-)-Ph;$   $-CH_2CH_2CH_2-NHSO_2-4-(4-Cl-Ph)-Ph;$  or  $-CH_2CH_2CH_2-NHSO_2-4-(naphth-2-yl)-Ph.$

25. A method for preparing an alkylated glycopeptide comprising: combining an aldehyde or ketone, a suitable base, and a compound of formula II:

HO NH CI OH OH OH 
$$CH_3$$
  $CH_3$   $CH_3$   $CH_3$ 

wherein:

5

 $R^{3} \text{ is } -OR^{c}, -NR^{c}R^{c}, -O-R^{a}-Y-R^{b}-(Z)_{x}, -NR^{c}-R^{a}-Y-R^{b}-(Z)_{x}, -NR^{c}R^{e}, \text{ or }$  -O-Re;

 $R^5$  is selected from the group consisting of hydrogen, halo,  $-CH(R^c)-NR^cR^c$ ,  $-CH(R^c)-NR^cR^e$ , and  $-CH(R^c)-NR^c-R^a-Y-R^b-(Z)$ ;

R<sup>19</sup> and R<sup>20</sup> are each hydrogen;

each R<sup>a</sup> is independently selected from the group consisting of alkylene,

substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

15

20

each R<sup>b</sup> is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkynylene and substituted alkynylene;

each R<sup>c</sup> is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)R<sup>d</sup>;

Re is a saccharide group;

each Y is independently selected from the group consisting of oxygen, sulfur,

each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; and

x is 1 or 2; or a stereoisomer or salt thereof; to provide a reaction mixture; acidifying the reaction mixture; and

combining the reaction mixture with a suitable reducing agent, to provide the corresponding alkylated glycopeptide wherein  $R^{20}$  is  $-R^a-Y-R^b-(Z)_x$ , alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkyl, or substituted cycloalkenyl.

```
26. The method of claim 25 wherein R<sup>20</sup> is -CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;

-CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>;

-CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-(CH<sub>2</sub>)<sub>11</sub>CH<sub>3</sub>;

-CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub>;

-CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub>;
```

```
CH=CH-(CH_{2})_{4}CH_{3}\ (trans);\ -CH_{2}CH_{2}CH_{2}CH_{2}CH_{2}CH_{2}-S-(CH_{2})_{7}CH_{3};\\ -CH_{2}CH_{2}-S(O)-(CH_{2})_{9}CH_{3};\ -CH_{2}CH_{2}-S-(CH_{2})_{6}Ph;\ -CH_{2}CH_{2}-S-(CH_{2})_{8}Ph;\\ -CH_{2}CH_{2}CH_{2}-S-(CH_{2})_{8}Ph;\ -CH_{2}CH_{2}-NH-CH_{2}-4-(4-Cl-Ph)-Ph;\\ -CH_{2}CH_{2}-NH-CH_{2}-4-[4-(CH_{3})_{2}CHCH_{2}-]-Ph;\ -CH_{2}CH_{2}-NH-CH_{2}-4-(4-CF_{3}-Ph)-Ph;\\ -CH_{2}CH_{2}-S-CH_{2}-4-(4-Cl-Ph)-Ph;\ -CH_{2}CH_{2}-S(O)-CH_{2}-4-(4-Cl-Ph)-Ph;\\ -CH_{2}CH_{2}CH_{2}-S-CH_{2}-4-(4-Cl-Ph)-Ph;\ -CH_{2}CH_{2}CH_{2}-S(O)-CH_{2}-4-(4-Cl-Ph)-Ph;\\ -CH_{2}CH_{2}CH_{2}-S-CH_{2}-4-[3,4-di-Cl-PhCH_{2}O-)-Ph;\ -CH_{2}CH_{2}-NHSO_{2}-CH_{2}-4-[4-(4-Cl-Ph)-Ph;\\ -CH_{2}CH_{2}CH_{2}-NHSO_{2}-CH_{2}-4-(4-Cl-Ph)-Ph;\\ -CH_{2}CH_{2}CH_{2}-NHSO_{2}-CH_{2}-4-(4-Cl-Ph)-Ph;\\ -CH_{2}CH_{2}CH_{2}-NHSO_{2}-CH_{2}-4-(Ph-C=C-)-Ph;\ -CH_{2}CH_{2}CH_{2}-NHSO_{2}-4-(4-Cl-Ph)-Ph;\\ 10 or\ -CH_{2}CH_{2}CH_{2}-NHSO_{2}-4-(naphth-2-yl)-Ph.
```

- 27. The method of claim 1, further comprising preparing a pharmaceutically acceptable salt of the alkylated glycopeptide.
- 28. The method of claim 1, further comprising, combining a pharmaceutically acceptable carrier with the alkylated glycopeptide to provide a pharmaceutical composition.
- 29. The method of claim 27, further comprising, combining a pharmaceutically acceptable carrier with the salt, to provide a pharmaceutical composition.